Cisplatin induces cytotoxicity through the mitogen-activated protein kinase pathways and activating transcription factor 3

Neoplasia

Volumn 12, Issue 7, 2010, Pages 527-538

  St Germain, Carly ^a,b   Niknejad, Nima ^a,b   Ma, Laurie ^a   Garbui, Kyla ^a,b   Hai, Tsonwin ^c   Dimitroulakos, Jim ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; CARBOPLATIN; CISPLATIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; ATF3 PROTEIN, MOUSE; CYTOTOXIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ANIMAL; CELL CULTURE; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; PHYSIOLOGY; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

ACTIVATING TRANSCRIPTION FACTOR 3; ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; CISPLATIN; CYTOTOXINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BRCA1; GENES, P53; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, TRANSGENIC; SIGNAL TRANSDUCTION;

EID: 77954998365     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.92048     Document Type: Article

References (43)

1. KellandL (2007). The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7, 573-584.
2. Stewart DJ (2007). Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 63, 12-31.
3. Siddik ZH (2003). Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22, 7265-7279.
4. Knox RJ, Friedlos F, Lydall DA, and Roberts JJ (1986). Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(l,l-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Research 46, 1972-1979.
5. Galanski M (2006). Recent developments in the field of anticancer platinum complexes. Recent Rat Anticancer Drug Discov 1, 285-295.
6. Manic S, Gatti L, Carenini N, Fumagalli G, Zunino F, and Perego P (2003). Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair. Curr Cancer Drug Targets 3, 21-29.
7. Sedletska Y, Giraud-Panis MJ, and Malinge JM (2005). Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways. Curr Med Cfaem Anticancer Agents 5, 251-265.
8. Liang G, Wolfgang CD, Chen BI Chen TH, and Hai T (1996).ATF3 gene. Genomic organization, promoter, and regulation. J Biol Chem 271, 1695-1701.
9. Hai Tand Hartman MG (2001). The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors: activating transcription factor proteins and homeostasis. Gene 273, 1-11.
10. Hsu JC, Laz T, Mohn KL, andTaub R (1991). Identification of LRF-1, a leucine-zipper protein that is rapidly and highly induced in regenerating liver. Proc Natl AcadSci USA 88, 3511-3515.
11. Chen BI Wolfgang CD, and Hai T (1996). Analysis of ATF3, a transcription factor induced by physiological stresses and modulated by gadd 153/ChoplO. Mol Cell Biol 16, 1157-1168.
12. Yin T, Sandhu G, Wolfgang CD, Burrier A, Webb RL, Rigel DF, Hai T, and Whelan J (1997). Tissue-specific pattern of stress kinase activation in ischemic/ reperfused heart and kidney. J Biol Chem 272, 19943-19950.
13. Takeda M, Kato H, Takamiya A, Yoshida A, and Kiyama H (2000). Injury-specific expression of activating transcription factor-3 in retinal ganglion cells and its colocalized expression with phosphorylated c-Jun. Invest Ophthalmol Vis Sci 41, 2412-2421.
14. Tsujino H, Kondo E, Fukuoka T, Dai Y, Tokunaga A, Mild K, Yonenobu K, Ochi T, and Noguchi K (2000). Activating transcription factor 3 (ATF3) induction by axotomy in sensory and motoneurons: a novel neuronal marker of nerve injury. Mol Cell Neurosci 15, 170-182.
15. Turchi L, Fareh M, Aberdam E, Kitajima S, Simpson F, Wicking C, Aberdam D, and Virolle T (2009). ATF3 and pl5PAF are novel gatekeepers of genomic integrity upon UV stress. Cell Death Differ 16, 728-737.
16. Bottone F G Jr, Moon Y, Kim J S, Alston-Mills B, Ishibashi M, and Eling T E (2005). The anti-invasive activity of cyclooxygenase inhibitors is regulated by the transcription factor ATF3 (activating transcription factor 3). Mol Cancer Ther 4, 693-703.
17. Fan F, Jin S, Amundson SA, Tong T Fan W, Zhao H, Zhu X, Mazzacurati L, Li X, Petrik KL, et al. (2002). ATF3 induction following DNA damage is regulated by distinct signaling pathways and over-expression of ATF3 protein suppresses cells growth. Oncogene 21, 7488-7496.
18. Lu D, Wolfgang C D, and Hai T (2006). Activating transcription factor 3, a stress-inducible gene, suppresses Ras-stimulated tumorigenesis. J Biol Chem 281, 10473-10481.
19. Yin X, Dewille JW, and Hai T (2008). A potential dichotomous role of ATF3, an adaptive-response gene, in cancer development. Oncogene 27, 2118-2127.
20. Syed V, Mukherjee K, Lyons-Weiler J, Lau KM, Mashima T, Tsuruo T and Ho SM (2005). Identification ofATF-3, caveolin-1, DLC-1, and NM23-H2 as putative antitumorigenic, progesterone-regulated genes for ovarian cancer cells by gene profiling. Oncogene 24, 1774-1787.
21. Shaulian E and Karin M (2001). AP-1 in cell proliferation and survival. Oncogene 20, 2390-2400.
22. Buganim Y, Kalo E, Brosh R, Besserglick H, Nachmany I, Rais Y, Stambolsky P, Tang X, Milyavsky M, Shats I, et al. (2006). Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction. Cancer Res 66, 10750-10759.
23. Zhang C, Gao C, Kawauchi J, Hashimoto Y, Tsuchida N, and Kitajima S (2002). Transcriptional activation of the human stress-inducible transcriptional repressor ATF3 gene promoter by p53. Biochem Biophys Res Commun 297, 1302-1310.
24. Harkin DP, Bean JM, Miklos D, Song YH, Truong VB, Englert C, Christians FC, Ellisen LW, Maheswaran S, Oliner JD, et al. (1999). Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell 97, 575-586.
25. Wek RC, Jiang HY, and Anthony TG (2006). Coping with stress: eIF2 kinases and translational control. Biochem Soc Trans 34, 7-11.
26. Hamdi M, Popeijus HE, Carlotti F, Janssen JM, van der Burgt C, Cornelissen-Steijger P, van de Water B, Hoeben RC, Matsuo K, and van Dam H (2008). ATF3 and Fral have opposite functions in JNK- and ERK-dependent DNA damage responses. DNA Repair (Amst) 7, 487-496.
27. Lu D, Chen J, and Hai T (2007). The regulation oi ATF3 gene expression by mitogen-activated protein kinases. Biochem J 401, 559-567.
28. Bragado P, Armesilla A, Silva A, and Porras A (2007). Apoptosis by cisplatin requires p53 mediated p38α MAPK activation through ROS generation. Apoptosis 12, 1733-1742.
29. Sanchez-Prieto R, Rojas JM, Taya Y, and Gutkind JS (2000). A role for the p38 mitogen-activated protein kinase pathway in the transcriptional activation of p53 on genotoxic stress by chemotherapeutic agents. Cancer Res 60, 2464-2472.
30. Kroupis C, Stathopoulou A, Zygalaki E, Ferekidou L, Talieri M, and Lianidou ES (2005). Development and applications of a real-time quantitative RT-PCR method (QRT-PCR) for BRCA1 mRNA. Clin Biochem 38, 50-57.
31. Janicke RU (2009). MCF-7 breast carcinoma cells do not express caspase-3. Breast Cancer Res Treat 117, 219-221.
32. Dimitroulakos J, Ye LY, Benzaquen M, Moore MJ, Kamel-Reid S, Freedman MH, Yeger H, and Penn LZ (2001). Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clin Cancer Res 7, 158-167.
33. Piacentini M, Fesus L, and Melino G (1993). Multiple cell cycle access to the apoptotic death programme in human neuroblastoma cells. FEBS Lett 320, 150-154.
34. Niknejad N, Morley M, and Dimitroulakos J (2007). Activation of the integrated stress response regulates lovastatin-induced apoptosis. J Biol Chem 282, 29748-29756.
35. Tassone P, Di Martino MT, Ventura M, Pietragalla A, Cucinotto I, Calimeri T, Bulotta A, Neri P, Caraglia M, and Tagliaferri P (2009). Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo. Cancer Biol Ther 8, 648-653.
36. Drexler H C (2009). Synergistic apoptosis induction in leukemic cells by the phosphatase inhibitor salubrinal and proteasome inhibitors. PLoS One 4, e4l6l.
37. Schewe D M and Aguirre-Ghiso J A (2009). Inhibition of eIF2a dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy. Cancer Res 69, 1545-1552.
38. Allan AL, Albanese C, Pestell RG, and LaMarre J (2001). Activating transcription factor 3 induces DNA synthesis and expression of cyclin Dl in hepatocytes. J Biol Chem 276, 27272-27280.
39. Wolfgang CD, Chen BP, Martindale JL, Holbrook NJ, and Hai T (1997). Gad 153/Chop 10, a potential target gene of the transcriptional repressor ATF3. Mol Cell Biol 17, 6700-6707.
40. Miyazaki K, Inoue S, Yamada K, Watanabe M, Liu Q, Watanabe T, Adachi MT, Tanaka Y, and Kitajima S (2009). Differential usage of alternate promoters of the human stress response geneATF3 in stress response and cancer cells. Nucleic Acids Res 37, 1438-1451.
41. Brozovic A and Osmak M (2007). Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett 251, 1-16.
42. Losa JH, Parada Cobo C, Viniegra JG, Sanchez-Arevalo Lobo VJ, Ramon y Cajal S, and Sanchez-Prieto R (2003). Role of the p38 MAPK pathway in cisplatin-based therapy. Oncogene 22, 3998-4006.
43. Olson J M and Hallahan A R (2004). p38 MAP kinase: a convergence point in cancer therapy. Trench Mol Med 10, 125-129.